[Estimating the potential of antioxidant therapy for patients with Parkinson's disease diagnosis].
The efficiency of using the natural antioxidant mexidol in a combined therapy of Parkinson's disease has been evaluated in a group of 65 patients including 29 females and 36 males. The drug was administered in the form of infusions (4-ml of a 5% solution per 200 - 250 ml of physiological solution) over a period of 10 days. The clinical dynamics was evaluated in terms of the universal parkinsonism disease rate scale (UPDRS) and using the data of electromyography and electroneuromyography. The 10-day treatment led to a reliable decrease in the level of postural tremor and static tremor, a decrease in the muscle tone, and an increase in the mobility and locomotor activity of patients. The maximum positive effect of mexidol was observed for patients in the initial stage of disease with tremor as predominant clinical syndrome. Neurophysiological evidence of the efficacy of mexidol therapy included a decrease in the level of volley activity manifested in the electromyograms and a decrease in the velocity of conduction over peripheral motor nerve fibers.
Katunina
E A
EA
D000328:Adult; D000368:Aged; D000975:Antioxidants / Q000494:pharmacology / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D004576:Electromyography / Q000187:drug effects; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010300:Parkinson Disease / Q000175:diagnosis / Q000188:drug therapy*; D010847:Picolines / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome
D000975:Antioxidants; D010847:Picolines; C070020:emoxypine succinate